Jeff Jiapeng Ruan, PhD
DownloadHi-Res Photo
Cards
Appointments
Digestive Diseases
Primary
Contact Info
Yale School of Medicine
Department of Medicine (Digestive Diseases), PO Box 208019
New Haven, CT 06520-8019
United States
About
Titles
Associate Research Scientist in Medicine (Digestive Diseases)
Appointments
Digestive Diseases
Associate Research ScientistPrimary
Other Departments & Organizations
Education & Training
- PhD
- Chinese Academy of Sciences (1998)
- MSc
- Nanjing University (1991)
- BA
- Hanzhong Teachers College (1985)
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Jeff Jiapeng Ruan's published research.
Publications Timeline
A big-picture view of Jeff Jiapeng Ruan's research output by year.
Pramod Mistry, MBBS, PhD, MA, MD
Shiny Nair, PhD
Sreeganga Chandra, PhD
Tamar Taddei, MD
6Publications
1Citations
Publications
2024
Digenic disorders in patients with Gaucher disease: Implications for clinical management and study of modifier genes
Saith A, Kasaiyan M, Ruan J, Basiri M, Mistry P. Digenic disorders in patients with Gaucher disease: Implications for clinical management and study of modifier genes. Molecular Genetics And Metabolism 2024, 141: 108026. DOI: 10.1016/j.ymgme.2023.108026.Peer-Reviewed Original ResearchConcepts
2023
Osteonecrosis in Gaucher disease in the era of multiple therapies: Biomarker set for risk stratification from a tertiary referral center
Basiri M, Ghaffari M, Ruan J, Murugesan V, Kleytman N, Belinsky G, Akhavan A, Lischuk A, Guo L, Klinger K, Mistry P. Osteonecrosis in Gaucher disease in the era of multiple therapies: Biomarker set for risk stratification from a tertiary referral center. ELife 2023, 12: e87537. PMID: 37249220, PMCID: PMC10317498, DOI: 10.7554/elife.87537.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsEnzyme replacement therapySubstrate reduction therapyAvascular osteonecrosisTertiary referral centerGaucher diseaseReferral centerTreatment initiationGD patientsImiglucerase enzyme replacement therapyResidual disease activityAnti-drug antibodiesYears of treatmentType of therapyRare inborn errorMixed-effects logistic modelGD1 patientsSpleen statusDisease activityClinical outcomesRisk stratificationReplacement therapyIndependent correlatesMultiple therapiesReduction therapyHigh riskSevere pulmonary arterial hypertension in Gaucher disease type 1
Basiri M, Ruan J, Nair S, Guo L, Mistry P. Severe pulmonary arterial hypertension in Gaucher disease type 1. Molecular Genetics And Metabolism 2023, 138: 107021. DOI: 10.1016/j.ymgme.2022.107021.Peer-Reviewed Original ResearchThe risk of hepatocellular carcinoma is markedly increased in Gaucher disease
Basiri M, Ruan J, Nair S, Lau H, Mistry P, Taddei T. The risk of hepatocellular carcinoma is markedly increased in Gaucher disease. Molecular Genetics And Metabolism 2023, 138: 107022. DOI: 10.1016/j.ymgme.2022.107022.Peer-Reviewed Original ResearchSingle cell resolution of neurodegeneration in Gaucher disease
Nair S, Belinsky G, Ruan J, Basiri M, Klinger K, Mistry P. Single cell resolution of neurodegeneration in Gaucher disease. Molecular Genetics And Metabolism 2023, 138: 107233. DOI: 10.1016/j.ymgme.2022.107233.Peer-Reviewed Original Research
2017
Glucosylsphingosine accelerates α-synuclein pathology in GBA-associated Parkinson disease
Taguchi Y, Liu J, Ruan J, Pacheco J, Zhang X, Abbasi J, Keutzer J, Mistry P, Chandra S. Glucosylsphingosine accelerates α-synuclein pathology in GBA-associated Parkinson disease. Molecular Genetics And Metabolism 2017, 120: s129. DOI: 10.1016/j.ymgme.2016.11.338.Peer-Reviewed Original Research
Links & Media
News
Get In Touch
Contacts
Mailing Address
Yale School of Medicine
Department of Medicine (Digestive Diseases), PO Box 208019
New Haven, CT 06520-8019
United States